ASCO, page-15

Well that is worth a response.

"All non-progressing 12 patients then graduated to NOX66 + carboplatin (AUC 6) for further 3 months" http://www.noxopharm.com/irm/PDF/1518_1/CorporatePresentationPostInterimClinicalDataRelease

Of that 12, 11 completed the next 3 month cycles

In that 3 months .... "4 SAEs (including 3 deaths) were reported" .
http://abstracts.asco.org/214/AbstView_214_218999.html

......Because no deaths were reported in the interim data and only one reaction to carb. "Only 1 patient (1/15) experienced toxicity serious enough to warrant withdrawal from the study due to an allergic reaction to the carboplatin"
http://www.noxopharm.com/irm/PDF/1507_1/NOXReportsNOX66ClinicalData

Score thus far those 11 pateinets 4 SAE (three dead), 2 PD 3 SD, zero PR zero CR and three to come.